Compare CCCC & LAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | LAW |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.7M | 274.2M |
| IPO Year | 2020 | 2021 |
| Metric | CCCC | LAW |
|---|---|---|
| Price | $3.84 | $3.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $12.20 | $8.00 |
| AVG Volume (30 Days) | ★ 2.9M | 457.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.45 | ★ 22.58 |
| EPS | N/A | ★ N/A |
| Revenue | $35,947,000.00 | ★ $156,849,000.00 |
| Revenue This Year | N/A | $11.23 |
| Revenue Next Year | N/A | $10.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.02 | ★ 8.29 |
| 52 Week Low | $1.36 | $2.45 |
| 52 Week High | $4.60 | $9.11 |
| Indicator | CCCC | LAW |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 45.36 |
| Support Level | $2.13 | $3.34 |
| Resistance Level | $3.89 | $5.00 |
| Average True Range (ATR) | 0.37 | 0.25 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 50.71 | 20.40 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.